Pfizer CEO: AI will help with medicine's next big breakthrough
View original at finance.yahoo.comPfizer CEO: AI will help with medicine's next big breakthrough Fresh off Pfizer's (PFE) $10 billion battle to acquire Metsera (MTSR), Pfizer chairman and CEO Albert Bourla tells Yahoo Finance Executive Editor Brian Sozzi that the future for the pharmaceutical giant is bright…
O que extraímos desta fonte
The claims Via News extracted from this document. We point to the source; we don't replace it.
Pfizer committed to invest $70 billion in the US over the next 3-5 years
80% confidenceVaccines will not go back to pre-Pasteur times long-term because vaccines have saved the world and are the most cost-effective medical intervention
80% confidenceMetsera has a monthly GLP-1 product and no one else is as advanced in monthly GLP-1
80% confidencePfizer plans to invest significantly to win in obesity space, following comprehensive and deep development plan
80% confidenceDrug pricing changes should be implemented beginning of the year 2026
80% confidencePresident Trump is more experienced in managing government in his second term and very determined
80% confidencePfizer will build manufacturing capacity for Metsera products in the US to provide US patients with US-produced anti-obesity drugs
80% confidenceAI will have a profound impact on medicine, with current capabilities exceeding what most companies are utilizing
80% confidenceMany medicines are dependent on China but Pfizer has no dependency - doesn't export from China or import anything from China to the US
80% confidenceBourla found collaboration with Kennedy very productive in many areas, including the HHS agreements announced at White House
80% confidenceIf a leader's defining characteristic is optimism, Bourla believes his is on the very high end of the spectrum
80% confidencePfizer has 11 manufacturing sites and 2 gigantic logistics centers (13 total) in the US, mostly in the South and Midwest
80% confidencePfizer's leading position will be in oncology in the near future, and will also play to be a leader in obesity
80% confidenceAI can help with target identification to find sites of cancer cells that create resistance to medicines and cause metastasis
80% confidencePfizer's two lead obesity assets failed one after the other about a year ago
80% confidenceConsumer drug prices on average are double the prices Pfizer charges in the US
80% confidenceThe acquisition's value depends on whether it works - if it works, it's worth the investment big time; if not, they overpaid
80% confidenceTrump is a disruptor who changes things people thought couldn't be changed
80% confidencePfizer has the right to win in the obesity space due to expertise in primary care, large-scale trials, manufacturing at scale, and top-ranked field force
80% confidenceBobby Kennedy would not have been Bourla's choice for HHS secretary, but he tries to work constructively
80% confidenceThe big discrepancy between affluent countries and the US in drug pricing was provocative and not sustainable
80% confidenceMetsera's oral peptides are well-formulated and don't require taking on empty stomach
80% confidenceAI can design medicines and molecules that fit targets much faster and better than traditional methods
80% confidenceBourla's optimism comes from his mother, a Holocaust survivor who emphasized that nothing is impossible
80% confidenceThe key challenge with AI is integrating it into business processes and operations, which creates anxiety and resistance
80% confidenceU.S. consumers pay for medicines as if they don't have insurance although they do, unlike hospital or MRI costs
80% confidencePfizer products from Metsera acquisition should hit market by 2028 if they move fast
80% confidenceAnimal testing for safety can be replaced in silico with AI models that accurately predict molecule behavior in toxicology and pharmacodynamics
80% confidencePfizer's primary care field force has been ranked number one consecutively for the last 10 years in the US
80% confidenceBourla and Kennedy have very big disagreements on vaccines and some scientific FDA approaches
80% confidence